CommercialPrior AuthHigh impact
Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-06-03)
Aetna·Pain Management, Neurology, Neurosurgery +3 more·Medical Policy
Effective date
Jun 3, 2026
We identified it
Aug 13, 2026
Summary
Aetna updated its peripheral electrical nerve stimulation policy (CPB 0011) effective June 3, 2026, clarifying coverage criteria for TENS, PENS, and implantable nerve stimulators. Key changes include strict trial period requirements (1-2 months for TENS), specific documentation standards, a limit of two CPT 64555 procedures per 365 days for implantable systems, and expanded exclusions for experimental indications (e.g., genicular nerve stimulation for knee pain, occipital neuralgia). Billing teams must update authorization workflows and claims validation immediately.
Action Required
By June 3, 2026, billing team must: (1) Update billing system to enforce maximum of TWO services of CPT 64555 per 365-day rolling period and reject claims exceeding this limit. (2) Implement prior authorization workflow requiring: documented trial period of 1-2 months with physician reevaluation, frequency/duration of use, pain relief results, and physician confirmation of medical necessity before authorizing continued TENS treatment. (3) Add clinical documentation requirements to authorization forms: For TENS—acute post-operative pain (≤30 days) OR chronic intractable pain with failed conservative treatment. For PENS—chronic low back pain with degenerative disc disease as part of multi-modality rehab including exercise, OR diabetic neuropathy/neuropathic pain with failure of 3+ medication classes (anticonvulsants, antidepressants, opioids, other agents). For implantable PNS—requires objective pathology evidence (EMG/NCS/diagnostic blocks), successful percutaneous trial (≥50% pain reduction for ≥3 days), no drug addiction, and no psychological contraindication. (4) Update claims rejection rules to deny coverage for experimental indications including: genicular nerves for knee pain, occipital neuralgia, post-herpetic neuralgia, saphenous nerve stimulation, suprascapular nerve entrapment, shoulder pain, intercostal neuralgia, medial branch nerve stimulation, and cluneal nerve stimulation. (5) Train billing and prior authorization staff on new exclusions and documentation requirements. Failure to implement these controls will result in claim denials and potential compliance violations.